The ACE2/apelin signaling, microRNAs, and hypertension

International Journal of Hypertension

Volumn 2015, Issue , 2015, Pages

  Chen, Lai Jiang ^a,b,c   Xu, Ran ^a,b   Yu, Hui Min ^d   Chang, Qing ^a,b   Zhong, Jiu Chang ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Key Laboratory of Hypertension Shanghai Institute of Hypertension   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; APELIN; MICRORNA; MICRORNA 1; MICRORNA 126; MICRORNA 130A; MICRORNA 132; MICRORNA 133A; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 155; MICRORNA 181B; MICRORNA 19B; MICRORNA 208; MICRORNA 212; MICRORNA 221; MICRORNA 222; MICRORNA 27A; MICRORNA 27B; MICRORNA 29; MICRORNA 365; MICRORNA 421; MICRORNA 424; MICRORNA 503; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIHYPERTENSIVE ACTIVITY; CELL PROLIFERATION; DRUG EFFECT; FIBROSIS; GENE EXPRESSION; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 84925424578     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2015/896861     Document Type: Review

References (48)

1. J. Y. Moon, "Recent update of renin-angiotensin-aldosterone system in the pathogenesis of hypertension, " Electrolytes and Blood Pressure, vol. 11, no. 2, pp. 41-45, 2013.
2. V. B. Patel, J.-C. Zhong, D. Fan et al. , "Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling, " Hypertension, vol. 64, no. 1, pp. 157-164, 2014.
3. Z. Zhang, L. Chen, J. Zhong, P. Gao, and G. Y. Oudit, "ACE2/ Ang-(1-7) signaling and vascular remodeling, " Science China Life Sciences, vol. 57, no. 8, pp. 802-808, 2014.
4. X.-H. Yu, Z.-B. Tang, L.-J. Liu et al. , "Apelin and its receptor APJ in cardiovascular diseases, " Clinica Chimica Acta, vol. 428, pp. 1-8, 2014.
5. X. Song, D. Shan, J. Chen, and Q. Jing, "miRNAs and lncRNAs in vascular injury and remodeling, " Science China Life Sciences, vol. 57, no. 8, pp. 826-835, 2014.
6. E. Bronze-da-Rocha, "MicroRNAs expression profiles in cardiovascular diseases, " BioMed Research International, vol. 2014, Article ID 985408, 23 pages, 2014.
7. S. Batkai and T. Thum, "MicroRNAs in hypertension: mechanisms and therapeutic targets, " Current Hypertension Reports, vol. 14, no. 1, pp. 79-87, 2012.
8. M. Ha and V. N. Kim, "Regulation of microRNA biogenesis, " Nature Reviews Molecular Cell Biology, vol. 15, no. 8, pp. 509-524, 2014.
9. A. Saj and E. C. Lai, "Control ofmicroRNA biogenesis and transcription by cell signaling pathways, " Current Opinion in Genetics and Development, vol. 21, no. 4, pp. 504-510, 2011.
10. C. C. Xu, W. Q. Han, B. Xiao, N. N. Li, D. L. Zhu, and P. J. Gao, "Differential expression of microRNAs in the aorta of spontaneously hypertensive rats, " Sheng Li Xue Bao, vol. 60, no. 4, pp. 553-560, 2008.
11. W.-H. Wu, C.-P. Hu, X.-P. Chen et al. , "MicroRNA-130a mediates proliferation of vascular smooth muscle cells in hypertension, " American Journal ofHypertension, vol. 24, no. 10, pp. 1087-1093, 2011.
12. J. E. Kontaraki, M. E. Marketou, E. A. Zacharis, F. I. Parthenakis, and P. E. Vardas, "Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension, " Journal ofHumanHypertension, vol. 28, no. 8, pp. 510-516, 2014.
13. J. E. Kontaraki, M. E. Marketou, E. A. Zacharis, F. I. Parthenakis, and P. E. Vardas, "MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potentialmarkers of target-organ damage, " Journal of the American Society of Hypertension, vol. 8, no. 6, pp. 368-375, 2014.
14. S. Li, J. Zhu, W. Zhang et al. , "Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection, " Circulation, vol. 124, no. 2, pp. 175-184, 2011.
15. E. Schulz, T. Gori, and T. Munzel, "Oxidative stress and endothelial dysfunction in hypertension, " Hypertension Research, vol. 34, no. 6, pp. 665-673, 2011.
16. L. Elia, M. Quintavalle, J. Zhang et al. , "Theknockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease, " Cell Death and Differentiation, vol. 16, no. 12, pp. 1590-1598, 2009.
17. T. Boettger, N. Beetz, S. Kostin et al. , "Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster, "The Journal of Clinical Investigation, vol. 119, no. 9, pp. 2634-2647, 2009.
18. M.-H. Kim, O. Ham, S.-Y. Lee et al. , "MicroRNA-365 inhibits the proliferation of vascular smooth muscle cells by targeting cyclin D1, " Journal of Cellular Biochemistry, vol. 115, no. 10, pp. 1752-1761, 2014.
19. B. Song, Z.-Z. Zhang, J.-C. Zhong et al. , "Loss of angiotensinconverting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway, " Circulation Journal, vol. 77, no. 12, pp. 2997-3006, 2013.
20. B. Hu, J. T. Song, H. Y. Qu et al. , "Mechanical stretch suppresses microRNA-145 expression by activating extracellular signalregulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype, " PLoS ONE, vol. 9, no. 5, Article ID e96338, 2014.
21. K. Kohlstedt, C. Trouvain, T. Boettger, L. Shi, B. Fisslthaler, and I. Fleming, "AMP-activated protein kinase regulates endothelial cell angiotensin-converting enzyme expression via p53 and the post-transcriptional regulation of microRNA-143/145, " Circulation Research, vol. 112, no. 8, pp. 1150-1158, 2013.
22. R. Goyal, D. Goyal, A. Leitzke, C. P. Gheorghe, and L. D. Longo, "Brain renin-angiotensin system: fetal epigenetic programming bymaternal protein restriction during pregnancy, " Reproductive Sciences, vol. 17, no. 3, pp. 227-238, 2010.
23. J. R. Kemp, H. Unal, R. Desnoyer, H. Yue, A. Bhatnagar, and S. S. Karnik, "Angiotensin II-regulated microRNA 483-3p directly targetsmultiple components of the rennin-angiotensin system, " Journal ofMolecular and Cellular Cardiology, vol. 75, pp. 25-39, 2014.
24. X. Jiang, Q. Ning, and J. Wang, "Angiotensin II induced differentially expressed microRNAs in adult rat cardiac fibroblasts, " Journal of Physiological Sciences, vol. 63, no. 1, pp. 31-38, 2013.
25. P. L. Jeppesen, G. L. Christensen, M. Schneider et al. , "Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes, " British Journal of Pharmacology, vol. 164, no. 2, pp. 394-404, 2011.
26. A. Sen, P. Most, and K. Peppel, "Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial cell dysfunction, " FEBS Letters, vol. 588, no. 6, pp. 906-914, 2014.
27. T. V. Eskildsen, P. L. Jeppesen, M. Schneider et al. , "Angiotensin II regulates microRNA-132/-212 in hypertensive rats and humans, " International Journal ofMolecular Sciences, vol. 14, no. 6, pp. 11190-11207, 2013.
28. T. V. Eskildsen, M. Schneider, M. B. Sandberg et al. , "The microRNA-132/212 family fine-tunes multiple targets in Angiotensin II signalling in cardiac fibroblasts, " Journal of the Renin-Angiotensin-Aldosterone System, 2014.
29. S. Gao, T.-W. Liu, Z. Wang et al. , "Downregulation of MicroRNA-19b contributes to angiotensin II-induced overexpression of connective tissue growth factor in cardiomyocytes, " Cardiology, vol. 127, no. 2, pp. 114-120, 2014.
30. L.-X. Yang, G. Liu, G.-F. Zhu et al. , "MicroRNA-155 inhibits angiotensin II-induced vascular smooth muscle cell proliferation, " Journal of the Renin Angiotensin Aldosterone System, vol. 15, no. 2, pp. 109-116, 2014.
31. G. Ceolotto, I. Papparella, A. Bortoluzzi et al. , "Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives, " The American Journal of Hypertension, vol. 24, no. 2, pp. 241-246, 2011.
32. D. W. Lambert, L. A. Lambert, N. E. Clarke, N. M. Hooper, K. E. Porter, and A. J. Turner, "Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421, " Clinical Science, vol. 127, no. 4, pp. 243-249, 2014.
33. Q. Gu, B. Wang, X.-F. Zhang, Y.-P. Ma, J.-D. Liu, and X.-Z. Wang, "Contribution of renin-angiotensin system to exerciseinduced attenuation of aortic remodeling and improvement of endothelial function in spontaneously hypertensive rats, " Cardiovascular Pathology, vol. 23, no. 5, pp. 298-305, 2014.
34. H.-J. Wang, W.-Y. Lo, and L.-J. Lin, "Angiotensin-(1-7) decreases glycated albumin-induced endothelial interleukin-6 expression via modulation of miR-146a, " Biochemical and Biophysical Research Communications, vol. 430, no. 3, pp. 1157-1163, 2013.
35. Y. Takahashi, M. Satoh, Y. Minami, T. Tabuchi, T. Itoh, and M. Nakamura, "Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels, " Clinical Science, vol. 119, no. 9, pp. 395-405, 2010.
36. C. M. Ferrario, J. Jessup, M. C. Chappell et al. , "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, " Circulation, vol. 111, no. 20, pp. 2605-2610, 2005.
37. J. C. Zhong, J. Y. Ye, H. Y. Jin et al. , "Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression, " Regulatory Peptides, vol. 166, no. 1-3, pp. 90-97, 2011.
38. J. Zhong, R. Basu, D. Guo et al. , "Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction, " Circulation, vol. 122, no. 7, pp. 717-728, 2010.
39. M. Satoh, Y. Takahashi, T. Tabuchi et al. , "Circulating Toll-like receptor 4-responsive microRNA panel in patients with coronary artery disease: results from prospective and randomized study of treatment with renin-angiotensin system blockades, " Clinical Science, vol. 128, no. 8, pp. 483-491, 2015.
40. T. Sato, T. Suzuki, H. Watanabe et al. , "Apelin is a positive regulator of ACE2 in failing hearts, " Journal of Clinical Investigation, vol. 123, no. 12, pp. 5203-5211, 2013.
41. N. E. Clarke and A. J. Turner, "Angiotensin-converting enzyme 2: the first decade, " International Journal of Hypertension, vol. 2012, Article ID 307315, 12 pages, 2012.
42. K. Tatemoto, M. Hosoya, Y. Habata et al. , "Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor, " Biochemical and Biophysical Research Communications, vol. 251, no. 2, pp. 471-476, 1998.
43. J. C. Zhong, X. Y. Yu, Y. Huang, L. M. Yung, C. W. Lau, and S. G. Lin, "Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice, " Cardiovascular Research, vol. 74, no. 3, pp. 388-395, 2007.
44. M. Przewlocka-Kosmala, T. Kotwica, A. Mysiak, and W. Kosmala, "Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction, " Journal of Hypertension, vol. 29, no. 5, pp. 971-979, 2011.
45. H. Najafipour, A. Soltani Hekmat, A. A. Nekooian, and S. Esmaeili-Mahani, "Apelin receptor expression in ischemic and non-ischemic kidneys and cardiovascular responses to apelin in chronic two-kidney-one-clip hypertension in rats, " Regulatory Peptides, vol. 178, no. 1-3, pp. 43-50, 2012.
46. R. Akcilar, S. Turgut, V. Caner et al. , "Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats, " Clinical and Experimental Hypertension, vol. 35, no. 7, pp. 550-557, 2013.
47. A. F. Ceylan-Isik, M. R. Kandadi, X. Xu et al. , "Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction, " Journal of Molecular and Cellular Cardiology, vol. 63, pp. 4-13, 2013.
48. J. Kim, Y. Kang, Y. Kojima et al. , "An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension, " Nature Medicine, vol. 19, no. 1, pp. 74-82, 2013.